Rosuvastatin 20mg 30 Tabs
THIS IS A BRAND MEDICATION
Mechanism of Action
Increases the number of hepatic LDL receptors on the cell surface, increasing the uptake and catabolism of LDL and inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
Ads., Adolescents and children ≥ 10 years with one aria hypercholesterolemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as tto. adjunct to diet when response to diet and other ttos. nonpharmacological (exercise, weight loss) has been inadequate. Tto Homozygous familial hypercholesterolemia. combined with diet and other ttos. lipid-lowering (LDL apheresis) or if such ttos. are not suitable. Prevention of major cardiovascular events in patients considered at high risk for a first cardiovascular event, as tto. adjuvant to correct other risk factors.
Oral. Dosage individualized.
- Tto. of hypercholesterolemia: initial 5-10 mg / day, if necessary, after 4 weeks increased to 10-20 mg / day; max. 40 mg / day (severe hypercholesterolaemia at high cardiovascular risk who do not achieve their goals tto. With 20 mg, need medical supervision). Children 10-17 years adolescent females at least 1 year after menarche: 5-20 mg / day.
- Prevention of cardiovascular events: 20 mg / day.
Elderly> 70 years: 5 mg / day. In or Asian patients with predisposing factors for myopathy: Recommended initial 5 mg / day.
I. R. Moderate: 5 mg / day.
Oral. Administered at any time of day with or without food.
Hypersensitivity, enf. active liver or unexplained persistent elevations of serum transaminases> 3 times ULN, IR severe myopathy, tto. concomitantly with cyclosporine, pregnancy and lactation, women of childbearing age.
Doses of 40 mg: patients with predisposing factors for myopathy / rhabdomyolysis. These factors include: I.R. moderate (CrCl <60 ml / min), hypothyroidism, personal or family history of hereditary muscular disorders, previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate, alcohol, situations that may be increased levels plasma, Asian patients, concomitant use of fibrates.
Warnings and Precautions
I. R. moderate enf history. liver and / or excessive alcohol consumption, race (increased Asian exposure). Monitor and discontinued if serum transaminases exceeding 3 times ULN. Risk of muscle disorders (myalgia, myopathy, and rarely rhabdomyolysis), monitor if there is tenderness, muscle weakness or muscle cramps. Prior to tto. caution in patients with predisposing factors for rhabdomyolysis (IR, hypothyroidism, personal or family history of Alzheimer's Disease. hereditary muscle, previous history of muscular toxicity with a statin or fibrate, alcohol, age> 70 years, concomitant with fibrates), determine values CK (not start if CK> 5 times ULN). Do not use with severe acute disorders of myopathy or predisposing to the development of IR 2 aria to rhabdomyolysis. In patients with hypercholesterolemia 2 aria caused by hypothyroidism or nephrotic syndrome, Crohn's Disease. underlying should be treated before starting tto. Not recommended concomitantly with protease inhibitors. Using contraceptive measures. Not recommended in children <10 years.
Contraindicated in enf. active liver.
Contraindicated in I. R. serious. and I. R. moderate (40 mg). Caution I. R. moderate (CrCl <60 ml / min) starting dose: 5 mg.
See Contraindications and Warnings and Precautions also:
Plasma concentration decreased by antacids (aluminum hydroxide and magnesium).
Increased intestinal motility caused by erythromycin.
Increased plasma levels: Hormone replacement therapy (ethinyl estradiol and norgestrel).
There are no data regarding excretion in human milk. Rosuvastatin is excreted in the milk of rats.
Effects on ability to drive
No studies have been conducted to determine the effect on the ability to drive or operate machinery. When driving vehicles or operating machines, it should be noted that dizziness may occur during treatment.
Diabetes, headache, dizziness, constipation, nausea, abdominal pain, myalgia, asthenia.
Drug Name: ROSUVASTATIN
Comparable patent medicine: Crestor
Active substance: Rosuvastatin
Concentration: 20 mg
Box with 30 tablets
Made in: Slovenia